Commissioner Ekaterina Zaharieva unveiled the European Life Sciences Strategy on July 2, 2025, advocating for a comprehensive plan to solidify Europe's position as a global leader in life sciences innovation. Rooted in recent pandemic lessons, the strategy emphasizes public safety while aiming to accelerate research and technological advances across medicine, biotechnology, and food systems.
Aiming at Increased EU Support and Collaboration Zaharieva stresses the importance of increased EU financial backing, noting an annual €10 billion allocation for this strategy within the current budget. Concrete measures include a new clinical research investment plan to boost Europe's declining share in global clinical trials by supporting multinational studies and shared research infrastructure, such as the EU Clinical Research Infrastructure Network and Bio-imaging facilities available in 18 countries.
Amplifying Advanced Therapies The plan aims to foster the development of advanced therapies—inclusive of cell and gene therapies—with commitments to safety, accessibility, and affordability. Establishing a European Network of Centres of Excellence and integrating funding within the Horizon Work Programmes represent concrete institutional and budgetary initiatives.
Balancing Regulation and Innovation The strategy promises a regulatory modernization through a proposed Biotech Act to simplify and expedite market access, while maintaining Europe's high safety standards. This reflects a political cleavage balancing stringent regulation versus accelerating innovation and investment attraction.
Talent Retention and Inclusion Addressing workforce challenges, especially for women in STEM, Zaharieva announces initiatives to improve career frameworks and educational outreach, aiming to retain and attract life science professionals within the EU.
Impact on Stakeholders For EU researchers and startups, the strategy offers substantial funding and infrastructure boosts, potentially accelerating innovation cycles. Biotechnology companies may benefit from faster regulatory pathways and increased investments, enhancing competitiveness. National authorities face intensified coordination roles and resource commitments, especially to integrate multi-country trials. Consumers stand to gain earlier access to innovative and safe therapies and healthier, sustainable food options, though the impacts depend on effective regulation and implementation.
Overall, Commissioner Zaharieva's strategy proposes a significant expansion of EU involvement and support for life sciences, positioning innovation and competitiveness alongside public safety and ethical standards, seeking a balanced evolution of regulation and market dynamics by 2030.
← Atlas › News › Industry, Innovation and Internal Market